Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER)

Kristin Skougaard, Olga Østrup, Kasper Guldbrandsen, Boe Sørensen, Peter Meldgaard, Zaigham Saghir, Peter Gørtz, Markus Nowak Lonsdale, Malene Støchkel Frank, Oke Gerke, Beata Agnieszka Rychwicka-Kielek, Gitte Persson, Lotte Holm Land, Tine Schytte, Uffe Bodtger, Halla Skuladottir, Jes Søgaard, Søren Steen Nielsen, Torben Riis Rasmussen, Barbara Malene Fischer*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.

Original languageEnglish
JournalClinical Lung Cancer
ISSN1525-7304
DOIs
Publication statusE-pub ahead of print - 21. Nov 2019

Fingerprint

Randomized Controlled Trials
Neoplasms
Quality of Life
DNA

Keywords

  • Liquid biopsies
  • NSCLC
  • PET/CT
  • QoL
  • Surveillance

Cite this

Skougaard, Kristin ; Østrup, Olga ; Guldbrandsen, Kasper ; Sørensen, Boe ; Meldgaard, Peter ; Saghir, Zaigham ; Gørtz, Peter ; Lonsdale, Markus Nowak ; Frank, Malene Støchkel ; Gerke, Oke ; Rychwicka-Kielek, Beata Agnieszka ; Persson, Gitte ; Land, Lotte Holm ; Schytte, Tine ; Bodtger, Uffe ; Skuladottir, Halla ; Søgaard, Jes ; Nielsen, Søren Steen ; Rasmussen, Torben Riis ; Fischer, Barbara Malene. / Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy : A Randomized Controlled Trial (SUPER). In: Clinical Lung Cancer. 2019.
@article{b649f7759381413e843f252ec6eb23c0,
title = "Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER)",
abstract = "Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.",
keywords = "Liquid biopsies, NSCLC, PET/CT, QoL, Surveillance",
author = "Kristin Skougaard and Olga {\O}strup and Kasper Guldbrandsen and Boe S{\o}rensen and Peter Meldgaard and Zaigham Saghir and Peter G{\o}rtz and Lonsdale, {Markus Nowak} and Frank, {Malene St{\o}chkel} and Oke Gerke and Rychwicka-Kielek, {Beata Agnieszka} and Gitte Persson and Land, {Lotte Holm} and Tine Schytte and Uffe Bodtger and Halla Skuladottir and Jes S{\o}gaard and Nielsen, {S{\o}ren Steen} and Rasmussen, {Torben Riis} and Fischer, {Barbara Malene}",
year = "2019",
month = "11",
day = "21",
doi = "10.1016/j.cllc.2019.11.002",
language = "English",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

Skougaard, K, Østrup, O, Guldbrandsen, K, Sørensen, B, Meldgaard, P, Saghir, Z, Gørtz, P, Lonsdale, MN, Frank, MS, Gerke, O, Rychwicka-Kielek, BA, Persson, G, Land, LH, Schytte, T, Bodtger, U, Skuladottir, H, Søgaard, J, Nielsen, SS, Rasmussen, TR & Fischer, BM 2019, 'Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER)', Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2019.11.002

Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy : A Randomized Controlled Trial (SUPER). / Skougaard, Kristin; Østrup, Olga; Guldbrandsen, Kasper; Sørensen, Boe; Meldgaard, Peter; Saghir, Zaigham; Gørtz, Peter; Lonsdale, Markus Nowak; Frank, Malene Støchkel; Gerke, Oke; Rychwicka-Kielek, Beata Agnieszka; Persson, Gitte; Land, Lotte Holm; Schytte, Tine; Bodtger, Uffe; Skuladottir, Halla; Søgaard, Jes; Nielsen, Søren Steen; Rasmussen, Torben Riis; Fischer, Barbara Malene.

In: Clinical Lung Cancer, 21.11.2019.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

T2 - A Randomized Controlled Trial (SUPER)

AU - Skougaard, Kristin

AU - Østrup, Olga

AU - Guldbrandsen, Kasper

AU - Sørensen, Boe

AU - Meldgaard, Peter

AU - Saghir, Zaigham

AU - Gørtz, Peter

AU - Lonsdale, Markus Nowak

AU - Frank, Malene Støchkel

AU - Gerke, Oke

AU - Rychwicka-Kielek, Beata Agnieszka

AU - Persson, Gitte

AU - Land, Lotte Holm

AU - Schytte, Tine

AU - Bodtger, Uffe

AU - Skuladottir, Halla

AU - Søgaard, Jes

AU - Nielsen, Søren Steen

AU - Rasmussen, Torben Riis

AU - Fischer, Barbara Malene

PY - 2019/11/21

Y1 - 2019/11/21

N2 - Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.

AB - Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.

KW - Liquid biopsies

KW - NSCLC

KW - PET/CT

KW - QoL

KW - Surveillance

U2 - 10.1016/j.cllc.2019.11.002

DO - 10.1016/j.cllc.2019.11.002

M3 - Journal article

C2 - 31839533

AN - SCOPUS:85076465561

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -